Our Focus

Strategic Partnerships

As we are close to completion of phase III with our lead product candidate P2B001 for early stage Parkinson’s disease treatment, we are looking for strategic partners for the worldwide marketing of this product, data readout is expected in Q4 2021 with regulatory filing soon after.

We are currently expanding our pipeline and actively searching for in licensing projects.Our main interest is in products in CNS and other diseases, where current treatments can be improved to address patients unmet need for optimized efficacy, safety, availability and convenience of use via 505(b)(2) products.